Curevo Vaccine

Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Cuervos goal is to rapidly advance innovative new vaccine candidates from the research laboratory to the clinic by joining forces with the South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington

Vaccines,adjuvants,public health,infectious disease,drug discovery,drug development,immunology,systems biology,and clinical trials

Curevo vaccine operates in the Biotechnology research industry.

Curevo vaccine's revenue is 11m - 100m

Curevo vaccine has 11 - 50 employees.